Physician profile
Bradley Weitzner
NPI 1598705188
$23,261.10
in general payments reported to CMS, 2019-2025
38 companies · $3,733 in 2025
The $3,733 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,407 · 2020: $2,425 · 2021: $2,451 · 2022: $2,622 · 2023: $4,180 · 2024: $4,443 · 2025: $3,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,058.18 |
| Education | $297.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,502.08 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,748.71 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Janssen Biotech, INC. | $2,433.21 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $2,301.63 | 2019-2025 | |
| Pfizer INC. | $1,934.83 | 2019-2025 | |
| Ucb, INC. | $1,788.13 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $1,314.12 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $1,257.29 | 2019-2025 | Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,196.40 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $805.16 | 2019-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $553.17 | 2021-2025 | Lupkynis |
| Fresenius Kabi USA, LLC | $312.41 | 2023-2025 | Idacio, Tyenne |
| Janssen Scientific Affairs, LLC | $301.68 | 2020-2025 | Tremfya |
| Actelion Pharmaceuticals US, INC. | $295.43 | 2023-2025 | Opsumit, Uptravi |
| Radius Health, INC. | $292.41 | 2019-2025 | Tymlos |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Weitzner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.